Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

The objective was to evaluate the prognostic impact of pre-transplant minimal residual disease (MRD) as determined by real-time quantitative polymerase chain reaction in 67 adult NPM1-mutated acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Twenty-eight of the 67 patients had a FLT3-ITD (42%). Median age at transplantation was 54.7 years, median follow-up for survival from time of allografting was 4.9 years. At transplantation, 31 patients were in first, 20 in second complete remission (CR) and 16 had refractory disease (RD). Pre-transplant NPM1 MRD levels were measured in 39 CR patients. Overall survival (OS) for patients transplanted in CR was significantly longer as compared to patients with RD (P=0.004), irrespective of whether the patients were transplanted in first or second CR (P=0.74). There was a highly significant difference in OS after allogeneic HSCT between pre-transplant MRD-positive and MRD-negative patients (estimated 5-year OS rates of 40 vs 89%; P=0.007). Multivariable analyses on time to relapse and OS revealed pre-transplant NPM1 MRD levels >1% as an independent prognostic factor for poor survival after allogeneic HSCT, whereas FLT3-ITD had no impact. Notably, outcome of patients with pre-transplant NPM1 MRD positivity >1% was as poor as that of patients transplanted with RD.

• Publication year

  2016

• Venue

  Blood Cancer Journal

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bcj.2016.46PMID 27471865PMCID 5030374
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia

  2016cited by this paper
• Assessment of Minimal Residual Disease in Standard-Risk AML.

  2016cited by this paper
• Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

  2015cited by this paper
• Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives

  2015cited by this paper
• Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML

  2014cited by this paper
• Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

  2014cited by this paper
• Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia

  2014cited by this paper
• Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.

  2014cited by this paper
• R: A language and environment for statistical computing.

  2014cited by this paper
• Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

  2014cited by this paper
• Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

  2014cited by this paper
• Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation

  2014cited by this paper
• The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.

  2013cited by this paper
• Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.

  2013cited by this paper
• Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation.

  2013cited by this paper
• Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.

  2013cited by this paper
• Acute myeloid leukaemia in adults.

  2013cited by this paper
• Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.

  2013cited by this paper
• Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

  2013cited by this paper
• Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

  2012cited by this paper
• Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

  2012cited by this paper
• The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

  2012cited by this paper
• Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

  2011cited by this paper
• Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.

  2011cited by this paper
• SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS

  2011cited by this paper
• NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression *

  2011cited by this paper
• Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

  2011cited by this paper
• Therapeutic advances in acute myeloid leukemia.

  2011cited by this paper
• Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

  2011cited by this paper
• Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

  2010cited by this paper
• Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives

  2009cited by this paper
• Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

  2009cited by this paper
• Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.

  2009cited by this paper
• The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

  2008cited by this paper
• Review Articles (434 articles)

  2008cited by this paper
• High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission

  2008cited by this paper
• Leading article

  2008cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning – is there still an upper age limit? A focus on myeloid neoplasia

  2007cited by this paper
• Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)

  2006cited by this paper
• Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations

  2006cited by this paper
• Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

  2006cited by this paper
• Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

  2005cited by this paper
• Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP)

  2005cited by this paper
• Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.

  2005cited by this paper
• Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

  2005cited by this paper
• Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.

  2005cited by this paper
• Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

  2005cited by this paper
• A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

  2004cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

  2002cited by this paper
• No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission

  2000cited by this paper
• Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission.

  2000cited by this paper
• Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

  1998cited by this paper
• Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

  1997cited by this paper
• Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia

  1997cited by this paper
• A note on quantifying follow-up in studies of failure time.

  1996cited by this paper
• Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.

  1994cited by this paper
• An Empirical Transition Matrix for Non-homogeneous Markov Chains Based on Censored Observations

  1978cited by this paper
• Regression models and life tables (with discussion

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Comparative Analysis of T‐Cell and Bone Marrow Chimerism for Relapse Prediction in Acute Leukaemia Post‐Transplantation

  2026influential citation
• Interplay between acute graft-versus-host disease and graft-versus-leukemia effect in pediatric acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: implications for relapse incidence and survival – an EBMT PDWP retrospective study

  2025cites this paper
• Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a‐rearranged acute myeloid leukemia

  2025cites this paper
• Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights

  2025influential citation
• Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications.

  2025cites this paper
• Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes.

  2025cites this paper
• Validation of a Multiplex mRNA- and gDNA-Based Droplet Digital PCR Assay in Acute Myeloid Leukemia Patients with an NPM1 Mutation.

  2025cites this paper
• Recent advances in AML with mutated NPM1

  2024cites this paper
• Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia

  2024cites this paper
• Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?

  2024cites this paper
• Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

  2024cites this paper
• Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

  2023cites this paper
• Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML

  2023cites this paper
• Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia

  2023cites this paper
• MRD-directed and risk-adapted individualized stratified treatment of AML.

  2023cites this paper
• Criteria for diagnosis and molecular monitoring of NPM1-mutated AML.

  2023cites this paper
• Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells

  2023cites this paper
• Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1- mutated acute myeloid leukemia

  2023cites this paper
• Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience

  2023cites this paper
• NPM1‐mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions

  2023cites this paper
• A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1‐mutated acute myeloid leukaemia in molecular failure

  2023cites this paper
• The clinical impact of the molecular landscape of acute myeloid leukemia

  2023cites this paper
• The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms

  2022cites this paper
• Acute myeloid leukemia risk models: Where do we stand?

  2022cites this paper
• Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group

  2022cites this paper
• Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy.

  2022cites this paper
• Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3‐ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation

  2022cites this paper
• Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia

  2021cites this paper
• Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse

  2021cites this paper
• Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field

  2021cites this paper
• Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1‐mRNA expression in patients with AML and MDS

  2021cites this paper
• Comparison of RNA‐ and DNA‐based methods for measurable residual disease analysis in NPM1‐mutated acute myeloid leukemia

  2021cites this paper
• Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns

  2021cites this paper
• Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia

  2021cites this paper
• Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?

  2021cites this paper
• Updates on targeted therapies for acute myeloid leukaemia

  2021cites this paper
• Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

  2021cites this paper
• Advances in acute myeloid leukemia

  2021cites this paper
• Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy

  2021cites this paper
• Measurable residual disease (MRD) monitoring by next-generation sequencing before allogeneic hematopoietic cell transplantation in AML

  2021cites this paper
• Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor: Hematopoietic Stem Cell Transplantation

  2020cites this paper
• How I diagnose and treat NPM1-mutated AML.

  2020cites this paper
• Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies

  2020cites this paper
• Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

  2020cites this paper
• NPM1-mutated acute myeloid leukemia: from bench to bedside.

  2020cites this paper
• Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation

  2020cites this paper
• Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor – Hematopoietic Stem Cell Transplantation: Single Center Experience

  2020cites this paper
• NPM1 Biology in Myeloid Neoplasia

  2020cites this paper
• The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse

  2020cites this paper
• Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

  2020cites this paper
• Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century

  2020cites this paper
• Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2020cites this paper
• How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.

  2019cites this paper
• Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease.

  2019cites this paper
• Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia

  2019cites this paper
• Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia

  2019cites this paper
• Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?

  2019cites this paper
• High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

  2019cites this paper
• Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study.

  2019cites this paper
• How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?

  2019cites this paper
• High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia

  2019cites this paper
• Strategies for minimal residual disease detection: current perspectives

  2019cites this paper
• What's new in consolidation therapy in AML?

  2019cites this paper
• Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?

  2019cites this paper
• Next Generation Sequencing for Measurable Residual Disease Detection in Acute Myeloid Leukemia

  2019cites this paper
• Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives

  2018influential citation
• Interaction between the immune system and acute myeloid leukemia: A model incorporating promotion of regulatory T cell expansion by leukemic cells

  2018cites this paper
• Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

  2018cites this paper
• Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression

  2018cites this paper
• Methods and role of minimal residual disease after stem cell transplantation

  2018cites this paper
• Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients

  2018cites this paper
• Advances in targeted therapy for acute myeloid leukaemia

  2018cites this paper
• Emerging molecular predictive and prognostic factors in acute myeloid leukemia

  2018cites this paper
• Clinical implications of molecular markers in acute myeloid leukemia

  2018cites this paper
• Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML

  2018cites this paper
• Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.

  2018cites this paper
• Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.

  2018cites this paper
• High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

  2018cites this paper
• Haematological Malignancies Targeting the FLT 3 Mutation in Acute Myeloid Leukaemia

  2017cites this paper
• Minimal Residual Disease in Acute Myeloid Leukemia

  2017cites this paper
• Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis

  2017cites this paper
• Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission

  2017cites this paper